CLAIMS:

[Claim 1] A combination therapy comprising an anti-cancer agent and an isolated peptide comprising the amino acid sequence denoted by SEQ ID NO. 1 or a pharmaceutically acceptable salt of said isolated peptide for use in a method of treating cancer, wherein said anti-cancer agent is selected from Taxol and doxorubicin.

[Claim 2] The combination therapy for use according to claim 1, wherein said anti-cancer agent is Taxol.

[Claim 3] The combination therapy for use according to claim 1 or 2, wherein said anti-cancer agent is doxorubicin.

[Claim 4] The combination therapy for use according to any one of claims 1 to 3, wherein said isolated peptide and said anti-cancer agent are administered concomitantly or consecutively.

[Claim 5] The combination therapy for use according to any one of claims 1 to 4, wherein said cancer is pancreatic cancer, ovarian cancer, spindle cell neoplasm of neural origin, spindle cell neoplasm, metastatic colorectal cancer, colon cancer, colorectal cancer, colon adenocarcinoma, rectal cancer, rectal adenocarcinoma, lung cancer, non-small cell lung carcinoma, spinal cord neoplasm, breast cancer, skin cancer, renal cancer, multiple myeloma, thyroid cancer, prostate cancer, adenocarcinoma, head and neck cancer, gastrointestinal cancer, stomach cancer, cancer of the small intestine, hepatic carcinoma, liver cancer or malignancies of the female genital tract**.**

[Claim 6] The combination therapy for use according to any one of claims 1 to 5, wherein said isolated peptide consists of the amino acid sequence denoted by SEQ ID NO. 1 or a pharmaceutically acceptable salt thereof.

[Claim 7] The combination therapy for use according to any one of claims 1 to 6, wherein said isolated peptide or a pharmaceutically acceptable salt thereof is administered:

a) at a dose of 5 mg/m^2 to 100 mg/m^2, and/or

b) at a frequency of once, twice or trice per week.

[Claim 8] A therapeutic kit comprising:

(a) an anti-cancer agent selected from Taxol and doxorubicin; and

(b) an isolated peptide comprising the amino acid sequence denoted by SEQ ID NO. 1 or a pharmaceutically acceptable salt of said isolated peptide,

[Claim 9] The therapeutic kit of claim 8, wherein said anti-cancer agent is Taxol.

[Claim 10] The therapeutic kit of claim 8, wherein said anti-cancer agent is doxorubicin.